Veeva Systems Inc. (VEEV) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. While there is optimism about Veeva AI and Crossix's growth, the lack of specific guidance and management's reluctance to provide detailed answers on key issues create uncertainty. Positive aspects include stable financial health, innovation in Safety, and a supportive market environment. However, concerns about CRM customer decisions and the absence of specific financial projections or guidance temper the overall sentiment. Given these mixed signals, the stock price reaction is likely to be neutral.
Key Financial Performance
Total Revenue $811 million, above guidance. No specific year-over-year percentage change or reasons for change mentioned.
Non-GAAP Operating Income $365 million, above guidance. No specific year-over-year percentage change or reasons for change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Veeva AI: Major initiative for Veeva with excellent progress, expected to be significant for customers, the industry, and Veeva.
Innovation across product areas: Significant innovation delivered across Vault CRM, Crossix, Clinical, and Safety.
Q3 Financial Performance: Total revenue of $811 million and non-GAAP operating income of $365 million, exceeding guidance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements and uncertainties: The company acknowledges that forward-looking statements regarding trends, strategies, and anticipated performance are subject to various risks and uncertainties, which could lead to actual results differing materially from expectations.
Dependence on Veeva AI initiative: The success of the Veeva AI initiative is critical for the company, and any failure to deliver on its potential could adversely impact customer satisfaction, industry positioning, and financial performance.
Regulatory and compliance risks: The company refers to risks listed in its earnings release and Form 10-Q, which likely include regulatory and compliance challenges that could impact operations and financial outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-looking statements: During the call, forward-looking statements were made regarding trends, strategies, and anticipated business performance, including guidance on future financial results. These statements are based on current views and expectations, subject to risks and uncertainties.
Guidance and updates: The company may discuss guidance during the call but will not provide further updates on performance during the quarter unless done in a public forum.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do you think about the size of the revenue at risk from the 6 customers potentially opting for other CRM solutions?
A:Brian Van Wagener stated that he would not size it but noted that CRM is about 20% of total revenue today, down from 25% two years ago. He mentioned that these are multiyear projects with no expected impact this year or likely next year, and no long-term impact on 2030 goals.
Q:Can you comment on the state of the EDC market and your pipeline for further market share gains?
A:Peter Gassner mentioned that one customer decided to go back to their previous provider but emphasized that this is not a trend. He highlighted opportunities in the pipeline for EDC with large sponsors and CROs, driven by the demand for integrated solutions across clinical operations and data. He also expressed excitement about next-generation clinical innovations.
Q:How should we think about the net impact of CRM attrition and the potential for offsets over the next 5 years?
A:Brian Van Wagener noted the potential for innovation in areas like service center, marketing, patient CRM, and AI. He mentioned that retained customers could adopt more products, and some customers have already started adding additional products. Peter Gassner added that the CRM business is healthy, with strong win and conversion rates, especially among smaller customers.
Q:What feedback have you received from customers regarding Veeva AI?
A:Peter Gassner stated that customers are looking for practical solutions that add value rapidly and prefer partners with deep domain knowledge. He highlighted specific use cases like insight generation in CRM and efficiency in safety case processing. Customers want robust and proven solutions, and Veeva is focused on delivering holistic AI value.
Q:What is the opportunity for AI in R&D, and how might it be monetized?
A:Peter Gassner mentioned that AI's value would be broadly distributed across areas like safety, clinical, commercial, and regulatory. He noted opportunities to reduce labor in safety and clinical areas and to improve insight generation and agility in commercial and regulatory areas.
Q:How are customers thinking about the size of their sales force with the implementation of AI?
A:Paul Shawah noted that while there have been some reductions in sales forces, the number of doctors has not changed, and a base level of sales reps is still needed. He mentioned potential productivity and effectiveness gains but expects stability in sales force size over the next few years.
Q:Can you elaborate on the demand environment and the financial health of the pharma end market?
A:Peter Gassner stated that the industry is healthy, with no material changes in customer buying behaviors. He highlighted the rapid evolution of science and the demand for curing uncured diseases as positive factors.
Q:Do you have any verbal indications from the remaining undecided top 20 CRM customers?
A:Peter Gassner declined to provide specific details, stating that they would notify when decisions are made but would not get into fine-grained updates.
Q:What is the outlook for Crossix, and how should we think about its growth trajectory?
A:Paul Shawah noted that Crossix has been performing well, with stable measurement business and strong audience performance. He expects it to be a growth driver over the next several years, supported by innovation and a shared data network with Compass.
Q:When might you see gross margin tailwinds as you work off Salesforce royalties?
A:Brian Van Wagener mentioned that there are short- to mid-term headwinds due to overlapping costs but expects these to be immaterial in the grand scheme. Gross margins on subscriptions are stable, and the impact will diminish over the next few years.
Q:Have you seen any changes in audience targeting on the Crossix platform due to regulatory focus on direct-to-consumer advertising?
A:Peter Gassner stated that digital marketing spending is increasing, and Crossix is becoming more of a standard. He emphasized the importance of measurement and optimization in digital channels.
Q:Are there any changes in the sales pipeline for Safety and regulatory products?
A:Peter Gassner noted that sales cycles for Safety and regulatory products remain long but highlighted momentum in Safety and the potential for AI to drive faster adoption. He also mentioned positive customer experiences from the IQVIA partnership.
Q:How does business consulting contribute to broader platform adoption?
A:Peter Gassner emphasized the integration of software, data, and consulting to deliver comprehensive solutions for life sciences. He noted that customers prefer a unified approach rather than piecing together solutions from multiple vendors.
Q:What is the innovation in Safety, and how is it being received?
A:Peter Gassner highlighted the architecture, AI, and analytics in Safety as key innovations. He noted that customers are hesitant to change Safety systems due to their complexity but expressed optimism about future adoption.
Q:What are the unique customer-specific factors driving some top 20 CRM customers to opt for other solutions?
A:Peter Gassner mentioned dynamics like individual preferences, cultural alignment, and a desire to try something new. He noted that custom-built systems might have shorter lifespans and could lead to win-back opportunities.
Q:How are you balancing go-to-market initiatives on the commercial side?
A:Paul Shawah stated that dedicated teams focus on different areas, allowing for simultaneous progress. He noted that CRM migration creates both challenges and opportunities, such as cross-sell potential in data and network products.
Q:How does the CRM market's competitive landscape impact your long-term position?
A:Paul Shawah emphasized Veeva's comprehensive Industry Cloud approach, integrating CRM with other products like Crossix and Commercial Content. He expressed confidence in Veeva's long-term market position due to its unique offerings and commitment to life sciences.
Q:What is the opportunity for Veeva Basics, and how does it fit into the broader ecosystem?
A:Peter Gassner noted that Veeva Basics helps smaller biotechs and supports the broader ecosystem. While not a major revenue driver, it provides a pathway for small companies to scale with Veeva as they grow.
Q:What are the learnings from the top 20 CRM customer decisions, and will it change your strategy?
A:Peter Gassner stated that Veeva's approach focused on customer success and transparency. He noted that the team is now focused on AI-driven innovations in CRM, which will differentiate future offerings.
Q:How do you view the potential for clinical AI agents, and what is the timeline for their development?
A:Paul Shawah mentioned that AI agents will be integrated into all software applications by 2026, starting with commercial and expanding to Safety, Quality, and clinical areas. He highlighted the potential for productivity gains and process streamlining.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the size of revenue at risk from the 6 CRM customers potentially opting for other solutions. They also declined to provide specific details on verbal indications from undecided top 20 CRM customers and did not elaborate on the timeline for potential win-backs.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Colby conference
Conference Instructions
Conference reminder
EVP Chief
Form Forward
Forward statement
Head Investor
Instructions Head
QA Chief
Relations afternoon
afternoon Conference
aid understanding
gentleman name
name Colby
pm Pacific
today fact
understanding result
website pm
VEEV Transcript
Veeva Systems Inc. (VEEV) Q1 2027 Earnings Call Transcript
Positive6-3
The earnings call summary indicates a positive outlook with strong financial performance and product development updates. Crossix's growth in digital channels and Falcon's potential as a new product are promising. Despite unchanged macro trends, Veeva's strategic acquisitions and CRM migration successes are positive indicators. The Q&A section revealed no major concerns, with management providing satisfactory answers. Overall, the sentiment is positive, suggesting a likely stock price increase.
Veeva Systems Inc. (VEEV) Q4 2026 Earnings Call Transcript
Positive3-4
The earnings call indicates a strong financial performance with a 15% YoY revenue increase and improved operating margins, suggesting operational efficiency. The free cash flow growth of 20% further supports a positive outlook. However, the absence of dividend or buyback programs slightly tempers the sentiment. No concerning details emerged from the Q&A session. Overall, the positive financial metrics and operational improvements suggest a positive stock price movement in the short term.
Veeva Systems Inc. (VEEV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Veeva Systems Inc. (VEEV) Presents at Raymond James TMT & Consumer Conference Transcript
Neutral12-8
VEEV Slides
Veeva Systems Q4’26 slides: revenue beats forecast, margins strong2026-03-04
Veeva Systems Q3 2026 slides: revenue jumps 16%, margins expand to 45%2025-11-20
Veeva Systems Q2 2026 slides: revenue up 17%, operating margins expand2025-08-27
Veeva Systems Q1 2026 slides: Revenue jumps 17% as operating margins hit 46%2025-05-28
VEEV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
